Table 3:
Adverse event (non-hematologic) | Dasatinib-resistant (Total 38 patients) N (%) | Dasatinib-intolerant (Total 50 patients) N (%) |
---|---|---|
Diarrhea | ||
All grade | 30 (79) | 42 (84) |
Grade 3/4 | 3 (8) | 5 (10) |
Nausea | ||
All grade | 20 (53) | 23 (46) |
Grade 3/4 | 1 (3) | 0 |
Vomiting | ||
All grade | 14 (37) | 24 (48) |
Grade 3/4 | 1 (3) | 0 |
Rash | ||
All grade | 10 (26) | 18 (36) |
Grade 3/4 | 0 | 3 (6) |
Pyrexia | ||
All grade | 6 (16) | 8 (16) |
Grade 3/4 | 0 | 0 |
Fatigue | ||
All grade | 8 (21) | 14 (28) |
Grade 3/4 | 0 | 1 (2) |
Abdominal pain | ||
All grade | 9 (24) | 12 (24) |
Grade 3/4 | 0 | 1 (2) |
Headache | ||
All grade | 8 (21) | 14 (28) |
Grade 3/4 | 1 (3) | 3 (6) |
Cough | ||
All grade | 7 (18) | 11 (22) |
Grade 3/4 | 0 | 0 |
Elevated ALT | ||
All grade | 6 (16) | 6 (12) |
Grade 3/4 | 0 | 4 (8) |
Upper abdominal pain | ||
All grade | 8 (21) | 9 (18) |
Grade 3/4 | 0 | 0 |
Arthralgia | ||
All grade | 5 (13) | 10 (20) |
Grade 3/4 | 0 | 1 (2) |
Decreased appetite | ||
All grade | 3 (8) | 7 (14) |
Grade 3/4 | 0 | 1 (2) |
Constipation | ||
All grade | 2 (5) | 8 (16) |
Grade 3/4 | 0 | 0 |
Dyspnea | ||
All grade | 2 (5) | 10 (20 |
Grade 3/4 | 0 | 1 (2) |
Back pain | ||
All grade | 5 (13) | 5 (10) |
Grade 3/4 | 0 | 2 (4) |
Dizziness | ||
All grade | 5 (13) | 8 (16) |
Grade 3/4 | 0 | 0 |
Peripheral edema | ||
All grade | 1 (3) | 5 (10) |
Grade 3/4 | 0 | 0 |
Nasopharyngitis | ||
All grade | 4 (11) | 5 (10 |
Grade 3/4 | 0 | 0 |
Extremity pain | ||
All grade | 1 (3) | 5 (10 |
Grade 3/4 | 0 | 0 |
Pleural effusion | ||
All grade | 5 (13) | 12 (24) |
Grade 3/4 | 2 (5) | 2 (4) |
Adverse event (hematologic) | ||
Thrombocytopenia | ||
All grade | 11 (29) | 19 (38) |
Grade 3/4 | 7 (18) | 16 (32) |
Anemia | ||
All grade | 8 (21) | 7 (14) |
Grade 3/4 | 3 (8) | 4 (8) |
Neutropenia | ||
All grade | 9 (24) | 7 (14) |
Grade 3/4 | 6 (16) | 7 (14) |
Abbreviations: ALT, alanine aminotransferase; CML, chronic myeloid leukemia